Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 7/20 | 0.39 |
| ▸ | BRAF | P15056 | 7/20 | 0.39 |
| ▸ | RET | P07949 | 5/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21465801 | 0.82 | KIT (0.48) | FGFR4SRCEGFRBRAFABL1 | |
| SCHEMBL30486114 | 0.81 | EGFR (0.46) | FGFR4SRCEGFRBRAFRET | |
| SCHEMBL22065344 | 0.78 | NR1H2 (0.61) | FGFR4NR1H2SRCEGFRBRAF | |
| SCHEMBL24533977 | 0.77 | NR1H2 (0.46) | FGFR4NR1H2SRCEGFRBRAF | |
| SCHEMBL21465752 | 0.77 | NR1H2 (0.59) | NR1H2SRCEGFRBRAFRET | |
| SCHEMBL24534127 | 0.76 | NR1H2 (0.49) | FGFR4NR1H2SRCEGFRBRAF | |
| SCHEMBL21470482 | 0.75 | GAA (0.48) | FGFR4SRCEGFRBRAFRET | |
| SCHEMBL21470954 | 0.72 | CHEK1 (0.46) | BRAFKDM4E | |
| SCHEMBL21471030 | 0.70 | NR1H2 (0.50) | FGFR4NR1H2SRCEGFRBRAF | |
| SCHEMBL29037742 | 0.69 | CCNA2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019200120-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | LYCERA CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |